ALAMEDA, Calif., and PARIS, March 6 Singulex Inc.announced today a collaboration with Novartis Pharma AG to give Novartisaccess to Singulex's advanced biomarker detection technology through anErenna(TM) Technology Access Program (ETAP). Terms of the collaboration werenot disclosed. In addition, the company announced the opening of a facilityin Paris, France to support the needs of Singulex's collaborators in Europe.
"We have gained tremendous traction with potential pharmaceutical partnersin the last year," said Philippe Goix, Ph.D., president and CEO of Singulex."Establishing this relationship with Novartis further validates the power ofour technology in therapeutic efficacy and toxicity programs."
As part of its ETAP partnership with Novartis, Singulex has placed itsflagship biomarker detection platform, the Erenna system, at Novartis' Basel,Switzerland facility and will be working with Novartis to develop biomarkerassays that have the potential to advance Novartis' drug development programs.Erenna and accompanying assays are designed to measure very low levels andsmall changes of protein biomarkers across a variety of biological samplesfrom multiple species.
"Among our goals is the establishment of strong collaborations withpharmaceutical companies that will bring advanced technologies to theirtranslational medicine and biomarker programs," continued Goix. "By opening afacility in Europe, we are bringing our strong immunoassay development skillsand Erenna technology closer to European partners. We are actively working toexpand our footprint across the globe, and this facility does just that."
Singulex develops and commercializes innovative technology solutions thatenable disease understanding and management for life science researchers andclinicians. Utilizing proprietary quantitative single molecule detectiontechnology, Singulex develops customized biomarker diagnostic systems that candetect and quantify normal and abnormal protein biomarkers in a variety ofbiological samples with extreme sensitivity and accuracy. Singulex iscurrently conducting several pilot studies with academic and moleculardiagnostic partners to validate the company's commercial digital moleculedetection platform, the Erenna(TM) Immunoassay System. Singulex's research anddevelopment facilities are located at the Center for Emerging Technologies inSt Louis, Missouri, and the company's commercial operations are based inAlameda, California. To learn more about Singulex, please visit us athttp://www.singulex.com.
The Erenna(TM) Technology Access Program (ETAP) offers select clients theopportunity to use Singulex's flagship Erenna system to improve and validatetheir vital immunoassays, adding as much as 1-3 logs of improvement insensitivity and providing less than 20% coefficient of variability. ETAPincludes the Erenna system, which is designed to detect and count singlemolecules, customized immunoassay development services, reagents, software anddirect and personal client service.
SOURCE Singulex Inc.